{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T04:33:31Z","timestamp":1792816411525,"version":"4.5.0"},"reference-count":31,"publisher":"American Society of Hematology","issue":"19","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,10,8]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>Allogeneic hematopoietic cell transplantation (HCT) is a potentially curative treatment strategy for patients with inborn errors of immunities (IEIs). The objective of this study was to assess the optimal busulfan exposure before allogeneic HCT for patients with an IEI who received an IV busulfan\u2013based conditioning regimen. Patients from 17 international centers were included. The main outcome of interest was event-free survival (EFS). Patients were categorized into 4 IEI subgroups: combined immunodeficiency (CID), severe combined immunodeficiency (SCID), neutrophil disorders, and hemophagocytic lymphohistiocytosis (HLH)\u2013related disorders. Busulfan exposure was calculated by individual centers (area under the curve [AUC]CENTER) and re-estimated using a nonlinear mixed\u2013effects model (NONMEM; exposure defined as AUCNONMEM). Overall, 562 patients were included: 173 (30.8%) with CID, 154 (27.4%) with SCID, 101 (18.0%) with HLH-related disorders, and 134 (23.8%) with neutrophil disorders. The median busulfan AUCNONMEM was 69.0\u00a0mg\u00a0\u00d7 h\/L and correlated poorly with the AUCCENTER (r2\u00a0=\u00a00.54). In patients with SCID, HLH-related, and neutrophil disorders with a busulfan AUCNONMEM of 70 to 90\u00a0mg\u00a0\u00d7 h\/L, 2-year EFS was superior to &amp;lt;70\u00a0mg\u00a0\u00d7 h\/L, and &amp;gt;90\u00a0mg\u00a0\u00d7h\/L. Full donor chimerism increased with higher busulfan AUCNONMEM, plateauing at 90\u00a0mg\u00a0\u00d7 h\/L. For patients with CID, the optimal AUCNONMEM for donor chimerism was found to be &amp;gt;70\u00a0mg\u00a0\u00d7 h\/L. Improved EFS and higher donor chimerism may be achieved by targeting a cumulative busulfan AUCNONMEM of 80\u00a0mg\u00a0\u00d7 h\/L (range, 70-90). Our study stresses the importance of uniformly using a validated population pharmacokinetic model to estimate AUCNONMEM.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2024013275","type":"journal-article","created":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T15:20:55Z","timestamp":1727450455000},"page":"5137-5145","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":21,"title":["Association of busulfan exposure and outcomes after HCT for patients with an inborn error of immunity"],"prefix":"10.1182","volume":"8","author":[{"given":"Tim","family":"Bogn\u00e0r","sequence":"first","affiliation":[{"name":"1Department of Clinical Pharmacy, University Medical Center Utrecht\/Wilhelmina Children's Hospital, Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0930-0611","authenticated-orcid":false,"given":"Moises","family":"Garcia-Rosa","sequence":"additional","affiliation":[{"name":"2Transplantation and Cellular Therapies, MSK Kids, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arief","family":"Lalmohamed","sequence":"additional","affiliation":[{"name":"1Department of Clinical Pharmacy, University Medical Center Utrecht\/Wilhelmina Children's Hospital, Utrecht, The Netherlands"},{"name":"3Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3261-1186","authenticated-orcid":false,"given":"Tayfun","family":"G\u00fcng\u00f6r","sequence":"additional","affiliation":[{"name":"4Division of Stem Cell Transplantation and Children's Research Center, University Children's Hospital Z\u00fcrich, University of Z\u00fcrich, Z\u00fcrich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4618-3319","authenticated-orcid":false,"given":"Mathias","family":"Hauri-Hohl","sequence":"additional","affiliation":[{"name":"4Division of Stem Cell Transplantation and Children's Research Center, University Children's Hospital Z\u00fcrich, University of Z\u00fcrich, Z\u00fcrich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4175-5728","authenticated-orcid":false,"given":"Susan","family":"Prockop","sequence":"additional","affiliation":[{"name":"5Dana-Farber\/Boston Children's Cancer and Blood Disorders Center, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Layne","family":"Oram","sequence":"additional","affiliation":[{"name":"5Dana-Farber\/Boston Children's Cancer and Blood Disorders Center, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0158-8147","authenticated-orcid":false,"given":"Sung-Yun","family":"Pai","sequence":"additional","affiliation":[{"name":"5Dana-Farber\/Boston Children's Cancer and Blood Disorders Center, Boston, MA"},{"name":"6Center for Cancer Research, National Cancer Institute, National Institutes of Health"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan","family":"Brooks","sequence":"additional","affiliation":[{"name":"7Division of Allergy, Immunology, and Bone Marrow Transplantation, Department of Clinical Pharmacy and Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rada M.","family":"Savic","sequence":"additional","affiliation":[{"name":"7Division of Allergy, Immunology, and Bone Marrow Transplantation, Department of Clinical Pharmacy and Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher C.","family":"Dvorak","sequence":"additional","affiliation":[{"name":"7Division of Allergy, Immunology, and Bone Marrow Transplantation, Department of Clinical Pharmacy and Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janel R.","family":"Long-Boyle","sequence":"additional","affiliation":[{"name":"7Division of Allergy, Immunology, and Bone Marrow Transplantation, Department of Clinical Pharmacy and Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4772-7031","authenticated-orcid":false,"given":"Maja","family":"Krajinovic","sequence":"additional","affiliation":[{"name":"8Centre de Canc\u00e9rologie Charles-Bruneau, Centre de recherche, Hospital Sainte-Justine Montr\u00e9al, Montr\u00e9al, QC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrique","family":"Bittencourt","sequence":"additional","affiliation":[{"name":"8Centre de Canc\u00e9rologie Charles-Bruneau, Centre de recherche, Hospital Sainte-Justine Montr\u00e9al, Montr\u00e9al, QC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Charlotte","family":"Teyssier","sequence":"additional","affiliation":[{"name":"8Centre de Canc\u00e9rologie Charles-Bruneau, Centre de recherche, Hospital Sainte-Justine Montr\u00e9al, Montr\u00e9al, QC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2353-860X","authenticated-orcid":false,"given":"Yves","family":"Th\u00e9or\u00eat","sequence":"additional","affiliation":[{"name":"8Centre de Canc\u00e9rologie Charles-Bruneau, Centre de recherche, Hospital Sainte-Justine Montr\u00e9al, Montr\u00e9al, QC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cary","family":"Martinez","sequence":"additional","affiliation":[{"name":"9Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1758-7779","authenticated-orcid":false,"given":"Toine C. G.","family":"Egberts","sequence":"additional","affiliation":[{"name":"1Department of Clinical Pharmacy, University Medical Center Utrecht\/Wilhelmina Children's Hospital, Utrecht, The Netherlands"},{"name":"3Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"Morales","sequence":"additional","affiliation":[{"name":"9Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Slatter","sequence":"additional","affiliation":[{"name":"10Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4493-8757","authenticated-orcid":false,"given":"Geoffrey D. E.","family":"Cuvelier","sequence":"additional","affiliation":[{"name":"11Pediatric Blood and Marrow Transplantation, CancerCare Manitoba, University of Manitoba, Winnipeg, MB, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Chiesa","sequence":"additional","affiliation":[{"name":"12Great Ormond Street Hospital for Children & Stem Cell Program, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert F.","family":"Wynn","sequence":"additional","affiliation":[{"name":"13Department of Blood and Marrow Transplant, Royal Manchester Children\u2019s Hospital, Manchester, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Coussons","sequence":"additional","affiliation":[{"name":"13Department of Blood and Marrow Transplant, Royal Manchester Children\u2019s Hospital, Manchester, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0371-3279","authenticated-orcid":false,"given":"Maria P.","family":"Cicalese","sequence":"additional","affiliation":[{"name":"14San Raffaele Telethon Institute for Gene Therapy, IRCCS San Raffaele Scientific Institute, Milan, Italy"},{"name":"15Faculty of Medicine and Surgery, Vita-Salute S. Raffaele University, Milan, Italy"},{"name":"16Pediatric Immunohematology and Bone Marrow Transplantation Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Ansari","sequence":"additional","affiliation":[{"name":"17Cansearch Research Platform in Pediatric Oncology and Hematology, Faculty of Medicine, Department of Pediatrics, Gynecology and Obstetrics, University of Geneva, Geneva, Switzerland"},{"name":"18Division of Pediatric Oncology and Hematology, Department of Women, Child and Adolescent, University Geneva Hospitals, Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2730-451X","authenticated-orcid":false,"given":"Susan E.","family":"Long","sequence":"additional","affiliation":[{"name":"19Division of Pediatric Blood and Marrow Transplant & Cellular Therapy, M Health Fairview Masonic Children's Hospital, University of Minnesota, Minneapolis, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2430-911X","authenticated-orcid":false,"given":"Christen L.","family":"Ebens","sequence":"additional","affiliation":[{"name":"19Division of Pediatric Blood and Marrow Transplant & Cellular Therapy, M Health Fairview Masonic Children's Hospital, University of Minnesota, Minneapolis, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3579-5996","authenticated-orcid":false,"given":"Hannah","family":"Lust","sequence":"additional","affiliation":[{"name":"20Stem Cell Transplant Program, Ann & Robert Lurie Children's Hospital, Northwestern University, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonali","family":"Chaudhury","sequence":"additional","affiliation":[{"name":"20Stem Cell Transplant Program, Ann & Robert Lurie Children's Hospital, Northwestern University, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1013-3646","authenticated-orcid":false,"given":"Christa E.","family":"Nath","sequence":"additional","affiliation":[{"name":"21Children's Hospital at Westmead, Sydney, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0101-4482","authenticated-orcid":false,"given":"Peter J.","family":"Shaw","sequence":"additional","affiliation":[{"name":"21Children's Hospital at Westmead, Sydney, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven J.","family":"Keogh","sequence":"additional","affiliation":[{"name":"21Children's Hospital at Westmead, Sydney, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7643-8592","authenticated-orcid":false,"given":"M. Y. Eileen C.","family":"van der Stoep","sequence":"additional","affiliation":[{"name":"22Department of Pediatrics, Willem Alexander Children's Hospital, Leiden University Medical Center, Leiden, The Netherlands"},{"name":"23Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, The Netherlands"},{"name":"24Center for Cell and Gene Therapy, Leiden University Medical Center, Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8151-1539","authenticated-orcid":false,"given":"Robbert","family":"Bredius","sequence":"additional","affiliation":[{"name":"22Department of Pediatrics, Willem Alexander Children's Hospital, Leiden University Medical Center, Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3984-5620","authenticated-orcid":false,"given":"Caroline A.","family":"Lindemans","sequence":"additional","affiliation":[{"name":"25Department of Pediatrics, University Medical Center Utrecht, Utrecht, The Netherlands"},{"name":"26Princess M\u00e1xima Center Utrecht, Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2232-6952","authenticated-orcid":false,"given":"Jaap-Jan","family":"Boelens","sequence":"additional","affiliation":[{"name":"2Transplantation and Cellular Therapies, MSK Kids, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9602-3407","authenticated-orcid":false,"given":"Imke H.","family":"Bartelink","sequence":"additional","affiliation":[{"name":"27Amsterdam University Medical Center, Location VUmc, Amsterdam, The Netherlands"},{"name":"28Cancer Center Amsterdam, Imaging and Biomarkers, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2024,9,27]]},"reference":[{"issue":"6","key":"2024100813002065600_bib1","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1016\/j.jaip.2019.02.013","article-title":"Health-related quality of life in children and adults with primary immunodeficiencies: a systematic review and meta-analysis","volume":"7","author":"Peshko","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"11","key":"2024100813002065600_bib2","doi-asserted-by":"crossref","first-page":"e526","DOI":"10.1016\/S2352-3026(16)30114-4","article-title":"Association of busulfan exposure with survival and toxicity after haemopoietic cell transplantation in children and young adults: a multicentre, retrospective cohort analysis","volume":"3","author":"Bartelink","year":"2016","journal-title":"Lancet Haematol"},{"issue":"4","key":"2024100813002065600_bib3","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.jtct.2022.01.013","article-title":"Association between the magnitude of intravenous busulfan exposure and development of hepatic veno-occlusive disease in children and young adults undergoing myeloablative allogeneic hematopoietic cell transplantation","volume":"28","author":"Bogn\u00e0r","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"7","key":"2024100813002065600_bib4","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1016\/j.bbmt.2019.03.008","article-title":"Low exposure busulfan conditioning to achieve sufficient multilineage chimerism in patients with severe combined immunodeficiency","volume":"25","author":"Dvorak","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"9","key":"2024100813002065600_bib5","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1182\/bloodadvances.2020001748","article-title":"Targeted busulfan-based reduced-intensity conditioning and HLA-matched HSCT cure hemophagocytic lymphohistiocytosis","volume":"4","author":"Felber","year":"2020","journal-title":"Blood Adv"},{"issue":"9915","key":"2024100813002065600_bib6","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/S0140-6736(13)62069-3","article-title":"Reduced-intensity conditioning and HLA-matched haemopoietic stem-cell transplantation in patients with chronic granulomatous disease: a prospective multicentre study","volume":"383","author":"G\u00fcng\u00f6r","year":"2014","journal-title":"Lancet"},{"issue":"11","key":"2024100813002065600_bib7","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1016\/j.bbmt.2012.05.006","article-title":"Busulfan, fludarabine, and alemtuzumab as a reduced toxicity regimen for children with malignant and nonmalignant diseases improves engraftment and graft-versus-host disease without delaying immune reconstitution","volume":"18","author":"Law","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"issue":"9","key":"2024100813002065600_bib8","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1016\/j.bbmt.2020.06.004","article-title":"Reduced toxicity conditioning for nonmalignant hematopoietic cell transplants","volume":"26","author":"Contreras","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"2024100813002065600_bib9","doi-asserted-by":"crossref","first-page":"258.e1","DOI":"10.1016\/j.jtct.2020.12.005","article-title":"The relationship between busulfan exposure and achievement of sustained donor myeloid chimerism in patients with non-malignant disorders","volume":"27(3)","author":"Apsel","year":"2021","journal-title":"Transplant Cell Ther"},{"issue":"6","key":"2024100813002065600_bib10","first-page":"760","article-title":"Busulfan interlaboratory proficiency testing program revealed worldwide errors in drug quantitation and dose recommendations","volume":"45","author":"Kweekel","year":"2023","journal-title":"Ther Drug Monit"},{"issue":"5","key":"2024100813002065600_bib11","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1097\/FTD.0000000000000862","article-title":"Quality control of busulfan plasma quantitation, modeling, and dosing: an interlaboratory proficiency testing program","volume":"43","author":"Mccune","year":"2021","journal-title":"Ther Drug Monit"},{"key":"2024100813002065600_bib12","unstructured":"European Medicine Agency. Guideline on bioanalytical method validation. 2011. Accessed 13 March 2024. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-bioanalytical-method-validation_en.pdf."},{"key":"2024100813002065600_bib13","unstructured":"US Department of Health and Human Services Food and Drug Administration\n          . Analytical procedures and methods validation for drugs and biologics guidance for industry. 2015. Accessed 13 March 2024. https:\/\/www.fda.gov\/files\/drugs\/published\/Analytical-Procedures-and-Methods-Validation-for-Drugs-and-Biologics.pdf."},{"issue":"5","key":"2024100813002065600_bib14","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1097\/FTD.0b013e31826051bb","article-title":"Predictive performance of a busulfan pharmacokinetic model in children and young adults","volume":"34","author":"Bartelink","year":"2012","journal-title":"Ther Drug Monit"},{"issue":"4","key":"2024100813002065600_bib15","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1097\/00007890-197410000-00001","article-title":"Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors","volume":"18","author":"Glucksberg","year":"1974","journal-title":"Transplantation"},{"issue":"1","key":"2024100813002065600_bib16","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.bbmt.2005.10.023","article-title":"Histopathologic diagnosis of chronic graft-versus-host disease: National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: II. Pathology Working Group report","volume":"12","author":"Shulman","year":"2006","journal-title":"Biol Blood Marrow Transplant"},{"issue":"11","key":"2024100813002065600_bib17","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1038\/s41409-020-0918-1","article-title":"Introduction of new pediatric EBMT criteria for VOD diagnosis: is it time-saving or money-wasting?: prospective evaluation of pediatric EBMT criteria for VOD","volume":"55","author":"Szmit","year":"2020","journal-title":"Bone Marrow Transplant"},{"issue":"5","key":"2024100813002065600_bib18","doi-asserted-by":"crossref","first-page":"331","DOI":"10.2165\/11598180-000000000-00000","article-title":"Body weight-dependent pharmacokinetics of busulfan in paediatric haematopoietic stem cell transplantation patients: towards individualized dosing","volume":"51","author":"Bartelink","year":"2012","journal-title":"Clin Pharmacokinet"},{"issue":"7","key":"2024100813002065600_bib19","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1007\/s40262-023-01275-x","article-title":"Population pharmacokinetic model of intravenous busulfan in hematopoietic cell transplantation: systematic review and comparative simulations","volume":"62","author":"Takahashi","year":"2023","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"2024100813002065600_bib20","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s40262-020-00947-2","article-title":"Review of the pharmacokinetics and pharmacodynamics of intravenous busulfan in paediatric patients","volume":"60","author":"Lawson","year":"2021","journal-title":"Clin Pharmacokinet"},{"issue":"9","key":"2024100813002065600_bib21","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1016\/j.bbmt.2019.05.021","article-title":"Harmonization of busulfan plasma exposure unit (BPEU): a community-initiated consensus statement","volume":"25","author":"McCune","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"13","key":"2024100813002065600_bib22","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1182\/blood-2018-01-828277","article-title":"Reduced-intensity conditioning for hematopoietic cell transplant for HLH and primary immune deficiencies","volume":"132","author":"Allen","year":"2018","journal-title":"Blood"},{"issue":"15","key":"2024100813002065600_bib23","doi-asserted-by":"crossref","first-page":"3754","DOI":"10.1182\/bloodadvances.2020002101","article-title":"Stem cell transplantation for children with hemophagocytic lymphohistiocytosis: results from the HLH-2004 study","volume":"4","author":"Bergsten","year":"2020","journal-title":"Blood Adv"},{"issue":"10","key":"2024100813002065600_bib24","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood.2023022281","article-title":"Survival in primary hemophagocytic lymphohistiocytosis, 2016 to 2021: etoposide is better than its reputation","volume":"143","author":"B\u00f6hm","year":"2024","journal-title":"Blood"},{"issue":"10","key":"2024100813002065600_bib25","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1182\/blood.2020005590","article-title":"Hematopoietic cell transplantation in chronic granulomatous disease: a study of 712 children and adults","volume":"136","author":"Chiesa","year":"2020","journal-title":"Blood"},{"issue":"17","key":"2024100813002065600_bib26","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1182\/blood-2018-03-840702","article-title":"SCID genotype and 6-month posttransplant CD4 count predict survival and immune recovery","volume":"132","author":"Haddad","year":"2018","journal-title":"Blood"},{"issue":"5","key":"2024100813002065600_bib27","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1016\/j.jaci.2021.10.017","article-title":"Hematopoietic cell transplantation in severe combined immunodeficiency: the SCETIDE 2006-2014 European cohort","volume":"149","author":"Lankester","year":"2022","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"9","key":"2024100813002065600_bib28","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1038\/s41409-021-01378-8","article-title":"EBMT\/ESID inborn errors working party guidelines for hematopoietic stem cell transplantation for inborn errors of immunity","volume":"56","author":"Lankester","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"2024100813002065600_bib29","doi-asserted-by":"crossref","first-page":"552","DOI":"10.3389\/fped.2019.00552","article-title":"Hematopoietic stem cell transplantation for combined immunodeficiencies, on behalf of IEWP-EBMT","volume":"7","author":"Neven","year":"2019","journal-title":"Front Pediatr"},{"issue":"1","key":"2024100813002065600_bib30","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1182\/hematology.2019000052","article-title":"Treatment of primary immunodeficiency with allogeneic transplant and gene therapy","volume":"2019","author":"Pai","year":"2019","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"4","key":"2024100813002065600_bib31","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1016\/j.jaci.2016.01.053","article-title":"Effect of stem cell source on long-term chimerism and event-free survival in children with primary immunodeficiency disorders after fludarabine and melphalan conditioning regimen","volume":"138","author":"Rao","year":"2016","journal-title":"J\u00a0Allergy Clin Immunol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/19\/5137\/2245458\/blooda_adv-2024-013275-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/19\/5137\/2245458\/blooda_adv-2024-013275-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T16:06:56Z","timestamp":1728403616000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/8\/19\/5137\/517221\/Association-of-busulfan-exposure-and-outcomes"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,27]]},"references-count":31,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2024,10,8]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2024013275","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,27]]}}}